Loading...
XSWX
YPSN
Market cap5.85bUSD
Jul 09, Last price  
358.60CHF
1D
2.11%
1Q
24.95%
Jan 2017
93.84%
IPO
381.34%
Name

Ypsomed Holding AG

Chart & Performance

D1W1MN
XSWX:YPSN chart
P/E
21.24
P/S
6.45
EPS
16.88
Div Yield, %
0.61%
Shrs. gr., 5y
1.47%
Rev. gr., 5y
12.61%
Revenues
731m
-2.39%
277,450,000287,468,000272,580,000254,014,000242,461,000248,593,000244,565,000276,257,000306,632,000336,922,000389,555,000466,119,000453,765,000394,264,000403,656,000464,841,000497,460,000548,457,000748,866,000730,982,000
Net income
222m
+153.62%
2,742,00026,583,00026,166,0009,425,0005,206,0008,500,0001,646,00013,608,00019,395,00035,812,00046,247,00052,060,00060,136,00011,734,0005,811,00023,105,00051,275,00078,366,00087,504,000221,927,000
CFO
307m
+106.99%
30,960,00070,155,00048,404,00022,480,00029,504,00031,055,00015,168,00041,206,00041,381,00076,687,00075,064,00053,269,00059,859,00049,089,00085,828,00085,706,000129,531,000163,224,000148,200,000306,759,000
Dividend
Jul 04, 20252.2 CHF/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Ypsomed Holding AG, along with its affiliates, specializes in the design, production, and sale of advanced injection and infusion delivery systems for pharmaceutical and biotechnology enterprises. The company structures its activities into two main divisions: Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment offers a broad array of innovative injection devices, including pen, auto, patch, and wearable injectors, as well as other smart medical technologies, all marketed under the YDS brand. Meanwhile, the Ypsomed Diabetes Care division is dedicated to providing vital products for diabetes management, such as insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, and various daily essentials, all sold under the mylife brand. Furthermore, the company extends its services to include precision turned parts and contract manufacturing. Its diverse product range is distributed through strategic partnerships with biotech and pharma companies, its own distribution infrastructure, and independent distributors. Established in 1984 and headquartered in Burgdorf, Switzerland, Ypsomed Holding AG maintains a significant presence across Switzerland, Europe, North America, and other international regions.
IPO date
Sep 22, 2004
Employees
2,059
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT